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Background. Neurocognitive deficits are important aspects of schizophrenic disorder because they have a strong impact
on social and vocational outcomes. Previously it was assumed that cognitive abilities progressively deteriorate with illness
onset. However, recent research results have contradicted this with observations of continuous or even improved perform-
ance in individuals at risk for psychosis or manifest schizophrenia. The objective of our longitudinal study was to examine
neurocognitive functioning in help-seeking individuals meeting basic symptoms or ultra-high-risk criteria for schizophrenic
psychosis (HRSchiz) or risk criteria for affective psychosis (HRBip). The progression of cognitive functioning in individuals
converting to psychosis was compared with that of at-risk individuals who did not convert during the follow-up period.
Method. Data were available from 86 study participants who completed neurocognitive and clinical assessments at
baseline and, on average, 12.8 (S.D. = 1.5) months later. Neurocognitive measures were grouped according to their load
in factor analysis to five cognitive domains: speed, attention, fluency, learning and memory, and working memory.
Results. Neurocognitive functioning in HRSchiz and HRBip individuals generally improved over time. Subjects convert-
ing to manifest psychosis displayed a stable neurocognitive profile from baseline to follow-up. Compared with non-con-
verters, they had already demonstrated a significantly lower level of performance during their baseline examinations.
Conclusions. Our data provide no evidence for a progressive cognitive decline in individuals at risk of psychosis. In line
with the neurodevelopmental model, our findings suggest that cognitive deficits are already present very early, before or
during the prodromal stage of the illness.
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Introduction
Schizophrenia has long been regarded as a progressive
brain disease that leads to severe cognitive and beha-
vioural decline (Jablensky, 2007; Zipursky et al. 2013).
Hence, there is a wealth of literature related to cogni-
tive functioning in patients with schizophrenia. On av-
erage, these individuals show cognitive deficits at a
level approximately 1–2 standard deviations (S.D.)
below the mean for healthy individuals (Heinrichs &
Zakzanis, 1998; Michie et al. 2000; Fioravanti et al.
2005). Brain-imaging studies have confirmed this by
demonstrating that alterations in brain structure and
presumably function may occur at some point in the
transition to full-blown psychosis (Zipursky et al.
1998; Shenton et al. 2001; Pantelis et al. 2003).
Researchers have proposed that different neuroregres-
sive processes, such as excessive pruning or inflamma-
tion starting in adolescence and early adulthood, are
the neurobiological substrate for this cognitive deterio-
ration (Insel, 2010; Bora & Murray, 2013).
Undoubtedly, a substantial portion of patients with
schizophrenia show a chronic course leading to a
high degree of disability (van Os & Kapur, 2009). It
has been suggested that after illness onset both patients
with schizophrenia and patients with bipolar disorder
may exhibit a decline in cognitive function. Thus, a
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meta-analysis revealed widespread general cognitive
deficits in both disorders, with quantitative rather
than qualitative differences between the diagnostic
groups (Stefanopoulou et al. 2009). However, the
view that this illness is inevitably progressive may
have emerged from a referral and sample bias
(Zipursky et al. 2013). That is, research on cognition
in schizophrenia may be biased toward those who
have been ill repeatedly or for many years (i.e. a preva-
lence sample) while those who have only brief periods
of illness are underrepresented (i.e. an incidence sam-
ple) (Cohen & Cohen, 1984). In addition, findings re-
garding the progression of cognitive deficits over the
course of the disorder may be conversely discussed
due to a heightened prevalence rate of confounding
variables associated with chronicity, such as other
co-morbid psychiatric diagnoses, antipsychotic medi-
cation, institutionalization, or poor physical health
(Fusar-Poli et al. 2012a). Those variables might equally
contribute to a negative course as might the progress-
ive nature of schizophrenia. Some researchers have
critically questioned whether schizophrenia is inher-
ently progressive and have suggested that the dis-
ability may result – unless referral and sampling
biases exist – from stable deficits that are established
before the onset of the illness (Becker et al. 2010; Bora
& Murray, 2013; Zipursky et al. 2013). In line with a
neurodevelopmental model of schizophrenia, recent
studies have provided evidence that cognitive and in-
tellectual deficits are apparent early in neurodevelop-
ment, several years before the onset of psychosis
(Cannon et al. 2006; Giuliano et al. 2012; Fusar-Poli
et al. 2012a; Müller et al. 2013; Bora et al. 2014). Birth co-
hort and conscript studies report strong associations
between poor performance on cognitive batteries and
increased risk of later schizophrenia (MacCabe, 2008;
MacCabe et al. 2008). Moreover, a systematic review
and meta-analysis confirmed the presence of a premor-
bid IQ deficit of around 0.5 S.D. among young people
who will later develop schizophrenia (Woodberry
et al. 2008). By contrast, premorbid deficits seem to
be absent, or even reversed, in bipolar disorder
(Koenen et al. 2009; MacCabe et al. 2010).
Evidence supporting cognitive deterioration in
schizophrenia is often based on indirect cross-sectional
comparisons among individuals at different sympto-
matic phases, e.g. chronic schizophrenia, first episode,
or at risk for psychosis (Bora & Murray, 2013). Such
observations of considerably less severe cognitive
deficits in at-risk individuals than in first-episode or
schizophrenia samples suggests a continuous decline
potentially related to neurobiological changes.
However, persons at risk may display fewer deficits
either because they are ‘earlier’ along the continuum
for psychosis or simply because of methodological
problems, such as heterogeneous inclusion criteria
(basic symptoms, high-risk, ultra-high risk) or moder-
ate transition rates in at-risk psychosis samples
(Ruhrmann et al. 2010; Simon & Umbricht, 2010;
Yung et al. 2010; Keshavan et al. 2011; Fusar-Poli et al.
2014). Furthermore, research related to the course of
cognition after a first episode of psychosis is inconsist-
ent (Kahn & Keefe, 2013). Some have reported that
cognitive ability remains stable or even improves by
the time of the follow-up assessment (Becker et al.
2010) while others have noted deterioration in certain
cognitive abilities (Brewer et al. 2006; Addington &
Barbato, 2012) or a relative cognitive decline compared
to healthy control subjects (Hedman et al. 2013).
Investigations to identify clinical or neurocognitive
markers in help-seeking individuals at risk for pro-
gression to bipolar disorder are still limited and incon-
sistent. A recent systematic review and meta-analysis
from Trotta et al. (2015) comparing premorbid and/or
post-onset global cognitive function between schizo-
phrenia and bipolar disorder found that compared to
healthy controls, schizophrenic patients showed a sign-
ificant premorbid cognitive impairment and a large
post-onset impairment. The bipolar disorder group
exhibited only small significant deficits in premorbid
intellectual function when this was assessed retrospec-
tively but not prospectively, and a moderate cognitive
impairment after onset. Results from an earlier pro-
spective birth cohort study showed that, early in the
developmental course of schizophrenia but not bipolar
disorder, impairments can arise in tasks that involve
psychomotor speed as well as attentional and execu-
tive abilities (Cannon et al. 2006). The conclusion has
been that these impairments may be specific to
schizophrenia-related rather than affective-disorder
outcomes. Other deficits in certain neurocognitive
domains, such as verbal memory and executive func-
tioning, are also potential predictors of bipolar disor-
ders Olvet et al. (2013). Thus, at-risk criteria for
bipolar disorder are still in an early stage of develop-
ment (Bechdolf et al. 2012). Because the presence of
hypomanic symptoms in adolescence is strongly pre-
dictive of later bipolar disorders, Angst et al. (2005)
have hypothesized that applying an instrument for
self-assessment of those symptoms might increase the
detection of such disorders.
Our study objective was to analyse the course of cog-
nitionandpsychopathological symptoms inhelp-seeking
individuals who initially met ultra-high-risk (Yung &
McGorry, 1996) and/or basic symptom criteria (Huber,
1966; Klosterkotter et al. 2001), defined as being at high
risk for schizophrenic psychosis (HRSchiz) at the time
of the baseline examination (reported in Metzler et al.
2014). These subjects were compared with help-seeking
individuals who met only the risk criteria for affective
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psychosis (high-risk bipolar; HRBip). Individuals at risk
of psychosis who did not convert were then compared
with the group of individuals actually converting to
psychosis during the follow-up period.
The following hypotheses were evaluated: (1) based on
the assumption that different neuroregressive processes,
such as excessive pruning or inflammation starting in
adolescence and early adulthood, are the neurobiological
substrate for the cognitive deterioration in schizophrenia
(Insel, 2010; Bora & Murray, 2013) a decline in cognitive
function with progression over time in prodromal indivi-
duals could be assumed; (2) during baseline testing, indi-
viduals converting to psychosis already exhibit a lower
level of cognitive performance compared with non-
converters; and (3) individuals at risk for affective
psychosis show a less severe decline than individuals at
risk for schizophrenic psychosis.
Method
Subjects
Individuals from the canton of Zurich, Switzerland,
were recruited within the context of a study on early
recognition of psychosis (ZInEP; in German: Zürcher
Impulsprogramm zur nachhaltigen Entwicklung der
Psychiatrie; www.zinep.ch). Potential participants
either had learned about this study from a project web-
site, flyers, or newspaper advertisements, or were re-
ferred to our staff by general practitioners, school
psychologists, counselling services, psychiatrists, or
psychologists. All subjects spoke proper German and
had normal or corrected-to-normal vision, normal
hearing, and normal motor limb function. Those
aged ≥18 years provided informed consent, while min-
ors (<18 years) gave assent in conjunction with parental
informed consent. The study was approved by the
canton’s Ethics Committee and was performed in
accordance with the Declaration of Helsinki.
Participants completed the neurocognitive assess-
ment shortly after inclusion (t0, baseline assessment)
and, on average, 12.8 (S.D. = 1.5) months later (t1,
follow-up assessment). Subjects who had experienced
a psychotic episode were tested when stabilized. In
the follow-up assessment, the same neurocognitive
tests were again performed. At baseline, neuropsycho-
logical data were available from 207 participants who
fulfilled the inclusion criteria (see psychopathological
assessment below) for high-risk (HR), ultra-high-risk
(UHR) or at-risk bipolar (HRBip). Exclusion criteria
for study participation were manifest schizophrenic,
substance-induced, or organic psychosis; current
substance or alcohol dependence; or an estimated ver-
bal IQ <80. For comparison, 50 healthy persons, com-
prising our control group (CG), completed the
neurocognitive assessment (for socio-demographic
descriptions see Metzler et al. 2014). Their qualifying
data suggested they were comparable in verbal intelli-
gence, level of education and gender to persons in the
other groups. Controls were screened with the Mini
International Neuropsychiatric Interview (MINI;
Sheehan et al. 1998) based on DSM-IV criteria to ex-
clude persons with any past or present psychiatric dis-
order. Moreover, control subjects with a neurological
or somatic disorder that might bias their cognition
were excluded from the study. None of the controls
were using psychotropic medication or illicit drugs.
At follow-up, complete psychopathological and neu-
rocognitive assessments were retrieved from 86 partici-
pants. In total, 34% of the individuals meeting risk
criteria were receiving psychotropic medication at
baseline and 47% were receiving at least one medi-
cation at follow-up. These medications included atypi-
cal antipsychotic medications (19% at baseline, 32% at
follow-up), mood stabilizers (1%, 1%), and antidepres-
sive medication (19%, 25%). Demographic data for
individuals in the follow-up analysis (N = 86) are
given in Table 1. Due to project-specific issues a follow-
up assessment of the CG could not be performed.
Psychopathological assessment
To qualify for inclusion, participants were required to
fulfil at least one of the following criteria at the baseline
examination.
(1) HR: high-risk status for psychosis, as assessed by
the Schizophrenia Proneness Interview, SPI-A
(Adult version) or SPI-CY (Children-Youth ver-
sion) (Schultze-Lutter et al. 2007; Schultze-Lutter
& Koch, 2009), having at least one cognitive-
perceptive basic symptom or at least two cognitive
disturbances, and not meeting any of the UHR in-
clusion criteria listed below.
(2) UHR: ultra-high-risk status for psychosis, as rated by
the Structured Interview for Prodromal Syndromes
(SIPS; Miller et al. 2003), having at least one attenu-
ated psychotic symptom, or at least one brief limited
intermittent psychotic symptom, or a state-trait cri-
terion [reduction in global assessment of functioning
(GAF; Endicott et al. 1976) of >30% in the past year,
plus either a schizotypal personality disorder or a
first-degree relative with psychosis].
(3) HRBip: high risk for bipolar disorder, as defined by
a score either ≥14 on the Hypomania Checklist
(HCL), a self-report measure of life-time hypomanic
symptoms (Angst et al. 2005), or a score ≥12 on the
Hamilton Depression Scale (HAMD; Schutte &
Malouff, 1995); and not meeting any of the at-risk
psychosis inclusion criteria listed above.
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A transition to schizophrenia or bipolar disorder was
diagnosed according to the International Classifica-
tion of Psychiatric Symptoms, version 10 (ICD-10).
Quantitative measures of psychopathology were further
obtained as follows: psychotic symptoms (Positive and
Negative Syndrome Scale, PANSS; Kay et al. 1987), cur-
rent Axis I co-morbidity via MINI (Sheehan et al. 1998),
general functioning per GAF, and satisfaction with their
psychosocial domains of life (Manchester Short
Assessment of Quality of Life, MANSA; Priebe et al.
1999). All assessments were conducted by trained, ex-
perienced psychiatrists or psychologists.
Neurocognitive assessment
A set of well-established neuropsychological tests was
administered in a fixed order at baseline and follow-up
(Table 2). The psychopathological and neurocognitive
assessments were conducted by different investigators;
hence neuropsychological testing and scoring were per-
formed blind to diagnostic status. Verbal IQ was esti-
mated with a German word recognition test (MWT-B;
Lehrl, 1989) for adults or a test of receptive vocabulary
for minors (PPVT; Dunn & Dunn, 2003). Test scores
were standardized by computing z scores based on the
performance of the CG. To reduce the amount of data
and examine generalized and specific deficits across cog-
nitive domains, scores were calculated for the indepen-
dent domains of speed, attention, fluency, learning and
memory, and working memory, as identified from the
factor analysis described by Metzler et al. (2014).
Statistical analysis
The dropout analysis was performed on the 207 indivi-
duals who participated in the baseline assessment. All
other analyses were performed with data obtained
from the 86 persons who participated in both baseline
and follow-up assessments. Subjects classified as HR
or UHR at baseline who did not convert during the
follow-up period were grouped together as at risk for
schizophrenic psychosis (HRSchiz, N = 60) and were
compared with those in the HRBip (N = 10) and con-
verter to schizophrenia (CONV) (N = 12) groups. The
group of converters to bipolar disorder (N = 4) was
considered too small and was excluded from analysis.
Demographic and clinical characteristics were com-
pared between groups, using χ2 and Fisher’s exact tests
Table 1. Demographic and clinical characteristics
HRSchiz HRBip CONV Test statistics
Na 60 10 12
Age at baseline (years ± S.D.) 20.8 (±6.1) 21.0 (±5) 19.1 (±4.8) F = 0.42, p = 0.65
Education (years ± S.D.) 10.3 (±3.1) 11.6 (±3.7) 10.0 (±2.1) F = 0.73, p = 0.48
Gender (F:M) 27:33 4:6 4:8 χ2 = 0.26, p = 0.06
Pre-morbid verbal IQ (mean ± S.D.) 105.0 (±12.0) 110.7 (±12.0) 94.8 (±7.4) F = 4.50, p = 0.006
Medication (mean ± S.D.)b
Baseline 13.5 (±41.0) 5.7 (±18.0) 98.4 (±170.0) F = 7.16, p = 0.001
Follow-up 34.2 (±82.0) 0.0 302.2 (±282.0) F = 23.94, p < 0.001
GAF (mean ± S.D.)
Baseline 55.9 (±13.9) 66.5 (±10.9) 52.2 (±14.0) F2,77 = 3.28, p = 0.05
Follow-up 66.0 (±13.8) 74.4 (±16.2) 54.7 (±20.2) F2,77 = 4.77, p = 0.01
PANSS (mean ± S.D.), positive symptom score
Baseline 13.1 (±3.8) 8.8 (±0.9) 16.5 (±4.6) F2,77 = 10.77, p < 0.001
Follow-up 10.6 (±3.3) 8.1 (±1.3) 15.5 (±7.0) F2,77 = 11.31, p < 0.001
PANSS (mean ± S.D.), negative symptom score
Baseline 13.8 (±5.7) 11.5 (±4.4) 20.2 (±5.7) F2,77 = 7.97, p = 0.001
Follow-up 11.8 (±4.6) 10.1 (±4.5) 22.1 (±6.6) F2,77 = 18.78, p < 0.001
PANSS (mean ± S.D.), general symptom score
Baseline 31.2 (±7.5) 26.4 (±3.6) 38.7 (±9.2) F2,77 = 7.74, p = 0.001
Follow-up 25.4 (±5.7) 21.8 (±3.6) 37.1 (±11.6) F2,77 = 16.52, p < 0.001
HAMD (mean ± S.D.)
Baseline 13.9 (±7.6) 10.5 (±5.3) 17.48 (±8.1) F2,77 = 2.39, p = 0.09
Follow-up 10.0 (±5.7) 6.2 (±2.3) 14.0 (±7.4) F2,77 = 4.06, p = 0.02
HRSchiz, High risk of schizophrenic psychosis; HRBip, high risk for bipolar disorder; CONV, Converter; GAF, Global
Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale; HAMD, Hamilton Depression Scale.
a Four converters to bipolar disorder are not displayed.
bChlorpromazine equivalents.
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for categorical variables or one-way analysis of variance
(ANOVA) with a Bonferroni post-hoc test for continuous
variables. Group comparisons of demographic and clini-
cal variables were performed using Pearson’s χ2 tests for
categorical variables and one-way ANOVAs for continu-
ous variables. Two-way repeated ANOVA was per-
formed for all cognitive variables and cognitive
domains as well as for the clinical variables with longi-
tudinal data of interest (Medication, GAF, PANSS posi-
tive, PANSS negative, PANSS general symptom score).
‘Group’ (HRSchiz, HRBip, and CONV) was entered as
the between-subjects factor while ‘Time’ (baseline and
follow-up) was the repeated measure. Chlorpromazine
equivalents (Andreasen et al. 2010) were added as a
covariate in all models. Paired t tests were used to com-
pare baseline and follow-up data within each group.
One-wayANOVAwith post-hocLSD testswere used to
compare the performance in the baseline assessment be-
tween the three groups (HRSchiz, HRBip, and CONV).
Bivariate correlations were conducted to examine
the relationships of score changes (endpoint score
minus baseline score) for both neurocognitive domains
and clinical symptoms, with the alpha level adjusted
using the Bonferroni procedure.
To analyse possible dropout features (sex, age, IQ,
psychopathological and cognitive variables), subjects
participating at both, baseline and follow-up assess-
ment (‘No drop-out’, nodrop: N = 86) were compared
with subjects missing the follow-up assessment [‘drop-
out’, drop: N = 121 (207− 86)]. All analyses were done
with SPSS v. 20.0 (SPSS Inc., USA).
Results
Demographic and clinical characteristics
Based on their demographic and clinical characteristics,
the participants within all groups had comparable
educational levels, ages, and gender (Table 1), but dif-
fered in their pre-morbid IQs and neuroleptic medica-
tions. That is, the HRSchiz and HRBip groups had
comparable IQs while the CONV group scored signifi-
cantly lower. Likewise, the amount of neuroleptic med-
ications utilized was comparable between HRSchiz and
HRBip but significantly higher for CONV. At baseline,
the three groups were not yet significantly different in
their GAF total scores, but they were at follow-up.
The CONV group displayed a significant lower GAF
score than HRSchiz and HRBip. By 1 year after complet-
ing the initial assessment, 15 of the 177 HRSchiz subjects
(8.4%) had converted to schizophrenic psychosis.
Considering only HRSchiz subjects with follow-up
neuropsychological testing, the transition rate within 1
year is 16%, as 12 of the 76 HRSchiz subjects had
converted to schizophrenic psychosis.
Psychopathological assessments
Repeated-measures analyses were used to examine
changes in psychopathological scores when Time and
Time ×Group interactions were considered. Significant
effects for Group were found for PANSS positive,
negative and general symptom score as well as for the
GAF score. A significant main effect for Time was
found for the PANSS positive symptom score (F1,77 =
4.84, p = 0.03), PANSS general symptoms (F = 1,77 = 8.45,
p = 0.005), and GAF (F1,77 = 7.48, p = 0.008). For the nega-
tive symptom score, no significant Time or Time ×
Group interaction was identified (all p > 0.15). Post-hoc
analysis revealed that, during follow-up assessment, all
groups showed improvements in positive symptoma-
tology, but only the improvement by the HRSchiz
group reached a statistically significant threshold (t =
4.92, p = 0.001). Whereas HRSchiz and HRBip improved
in negative symptom scores (t = 2.40, p = 0.02), CONV
Table 2. Neurocognitive assessment
Functional domain Test Variable
Pre-morbid verbal IQ Vocabulary test: Mehrfachwahl-Wortschatz-Intelligenztest (MWT; Lehrl,
1989); Peabody Picture Vocabulary Test (PPVT; Dunn & Dunn, 2003)
Raw score correct
Speed Trail-Making Test, Version A and B (TMT-A/B; Reitan & Wolfson, 1985) Time to complete test
Digit Symbol Coding Test (DSCT; Subtest of Wechsler Adult Intelligence
Scale; German Version, Aster et al. 2006)
Number correct
Attention Continuous Performance Test (CPT-OX; Beck et al. 1956) Reaction time, number
of omissions
Fluency Fluency Test, S-Words and Animals (RWT; Regensburger
Wortflüssigkeitstest; Aschenbrenner et al. 2000)
Number correct
Learning/Memory Rey Auditory Verbal Learning Test (RAVLT; Helmstaedter et al. 2001), Rey
Visual Design and Learning Test (RVDLT; Spreen & Strauss, 1991)
T1, ∑T1-T5, Delayed
recall, recognition
Working memory Digit Span and Letter-Number Sequencing (DS and LNS; Subtests ofWechsler
Adult Intelligence Scale, German Version, Aster et al. 2006)
Number correct
Changes in neurocognitive function in individuals at risk for psychoses 5
displayed more negative symptoms at follow-up.
The general symptoms of CONV remained unchanged
(t = 0.03, p = 0.97) while HRSchiz (t = 5.20, p = 0.001) and
HRBip (t = 3.24, p = 0.01) significantly improved. The
GAF scores for both HRSchiz and HRBip were signifi-
cantly improved (t =−4.44, p = 0.001, and t =−2.61, p =
0.02, respectively), while that of CONV remained un-
changed (t =−0.48, p = 0.63).
Neurocognitive domains
The neuropsychological profiles for the three clinical
groups at baseline and follow-up are displayed in
Fig. 1. Repeated-measures analyses were used to exam-
ine Group, Time, and Time × Group interactions.
Significant effects for Group were found for the
domains of speed, learning/memory, working mem-
ory, and fluency. Effects for Time were found for the
domains of learning/memory and fluency, while a
significant Time × Group interaction effect was noted
for the fluency domain (Table 3). Post-hoc analysis
revealed that, in the speed domain, HRSchiz showed
improvement (t = 5.33, p = 0.0001) while the HRBip
and CONV groups remained stable. In the attention
domain, HRSchiz showed a slight improvement over
time (t =−2.07, p = 0.04), while the HRBip (t =−0.42,
p = 0.67) and CONV groups had equal and consistent
performances (t = 1.32, p = 0.22). In the fluency
domain, the HRSchiz (t =−2.92, p = 0.005), and HRBip
(t =−2.37, p = 0.04) groups improved significantly
over time, while the CONV group remained stable
(t = 0.61, p = 0.55). In the learning/memory domain,
HRSchiz improved over time (t =−3.13, p = 0.003),
while those improvements were not statistically signifi-
cant in either the HRBip or CONV groups (all p > 0.05).
In the working memory domain, no significant
improvement was noted for any group (all p > 0.05).
At baseline, the level of performance differed in the
domains of speed (F = 4.30, df = 2, p = 0.04), attention
(F = 3.18, df = 2, p = 0.04), learning/memory (F = 4.19,
df = 2, p = 0.01), working memory (F = 5.77, df = 2, p =
0.005), and fluency (F = 7.68, df = 2, p = 0.001). Post-hoc
analyses revealed that CONV performed at a signifi-
cantly lower level than HRSchiz and HRBip in the
domains of speed (p = 0.04), learning/memory (p = 0.03),
working memory (p = 0.01), and fluency (p = 0.002).
Bivariate correlations between neurocognitive and
clinical change scores across all groups revealed a
negative association of the fluency domain with the
PANSS positive symptoms scale (r = 0.306, p = 0.006).
The results of other comparisons did not survive the
Bonferroni correction.
With regard to our analysis of dropout features, a χ2 test
showed that the genders were equally distributed in the
nodrop and drop groups (χ2 = 1.71, df = 1, p = 0.19). No
significant differences were found between those groups
in terms of mean age at intake and mean premorbid IQ
(t = 1.27, df = 205, p = 0.20, and t =−1.32, df = 205, p = 0.18,
respectively). For the baseline assessment, none of the
other psychopathological features (GAF score, HAMD,
HCL, MANSA, PANSS) or cognitive domains differed
significantly between nodrop and drop (all p > 0.05).
Discussion
In this study, the range of neurocognitive performance
was examined in a sample of individuals at risk for
schizophrenic or affective psychoses, and subjects
converting to psychosis during the follow-up period.
Our findings suggested that first, non-converting
individuals at risk for schizophrenic psychosis and
Fig. 1. Mean z scores for high risk of schizophrenic psychosis (HRSchiz), converter (CONV), and high risk for bipolar
disorder (HRBip) groups at baseline (t0) and follow-up (t1).
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Table 3. Domain scores (z scores) and test scores (raw score) for the three clinical groups at baseline and follow-up
Baseline Follow-up
HRSchiz CONV HRBip HRSchiz CONV HRBip Test statistics
Domain Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Time (p) Time x group (p)
Speed −0.79 1.02 −1.61 1.60 −0.67 0.99 −0.39 0.95 −1.58 1.38 −0.34 0.84 F1,79 = 3.70 (0.05) F2,79 = 1.63 (0.20)
TMT_A 26.85 7.00 30.47 16.04 25.74 8.05 23.75 6.60 30.90 13.75 25.29 6.52 F1,79 = 0.92 (0.34) F2,79 = 1.70 (0.90)
TMT_B 61.01 19.94 67.53 17.81 52.61 15.75 53.80 17.45 63.77 19.62 53.98 22.55 F1,79 = 1.70 (0.20) F2,79 = 0.83 (0.44)
DSCT 73.04 14.58 57.00 14.98 73.22 12.04 77.69 14.77 56.73 10.01 81.56 10.60 F1,79 = 4.29 (0.04)* F2,79 = 1.48 (0.24)
Attention −1.47 2.65 −1.83 2.60 −0.15 0.69 −1.11 2.46 −1.94 1.66 −0.12 0.98 F1,79 = 0.34 (0.56) F2,79 = 1.14 (0.32)
CPT_RT 478.80 117.90 528.80 89.90 450.10 74.50 467.25 118.80 500.92 101.50 434.00 66.80 F1,79 = 1.26 (0.26) F2,79 = 0.00 (0.99)
CPT_Omis 2.16 4.09 1.90 4.33 0.10 0.31 2.04 3.93 4.50 5.70 0.80 0.91 F1,79 = 2.89 (0.09) F2,79 = 1.86 (0.16)
Learning/memory −0.69 0.88 −1.30 0.90 −1.90 1.03 −0.39 0.98 −1.05 1.01 0.16 0.65 F1,79 = 7.20 (0.009)** F2,79 = 0.06 (0.94)
RAVLT_T1 7.51 2.00 6.73 0.90 9.00 2.50 8.17 2.30 7.58 2.90 9.30 2.20 F1,79 = 6.85 (0.01)* F2,79 = 0.75 (0.47)
RAVLT_ΣT1-5 55.38 9.20 49.60 6.80 61.50 11.10 57.17 11.8 53.00 9.30 63.50 7.50 F1,79 = 2.92 (0.09) F2,79 = 0.36 (0.69)
RAVLT_recall 11.57 2.90 8.82 2.00 13.60 2.80 12.35 2.60 10.42 3.60 14.20 1.00 F1,79 = 10.20 (0.00)** F2,79 = 0.63 (0.20)
RAVLT_recogn 13.53 2.10 12.73 2.50 13.90 2.80 13.85 1.90 13.08 1.80 14.40 1.00 F1,79 = 1.88 (0.17) F2,79 = 0.12 (0.88)
RVDLT_T1 5.32 2.20 5.17 1.90 5.60 2.30 6.25 2.30 5.42 2.20 7.00 2.20 F1,79 = 5.49 (0.02)* F2,79 = 0.62 (0.53)
RVDLT_ ΣT1-5 50.80 10.20 46.58 13.10 53.60 9.90 53.52 10.50 44.58 10.80 59.70 7.30 F1,79 = 3.01 (0.08) F2,79 = 2.36 (0.10)
RVDLT_recall 12.58 2.30 11.00 3.10 13.40 2.00 12.98 2.20 10.92 3.80 13.80 1.60 F1,79 = 0.51 (0.47) F2,79 = 0.24 (0.78)
RVDLT_recogn 14.05 1.20 13.00 3.00 14.60 0.50 14.45 0.90 13.75 1.70 14.70 0.60 F1,79 = 3.20 (0.07) F2,79 = 0.51 (0.60)
Working memory −0.76 0.80 −1.43 0.95 −0.26 0.81 −0.63 0.91 −1.44 0.69 −0.23 0.94 F1,79 = 0.32 (0.57) F2,79 = 0.31 (0.74)
DS_total 16.58 3.30 13.00 3.80 18.30 4.70 16.85 3.80 13.33 3.30 18.30 3.60 F1,79 = 0.30 (0.58) F2,79 = 0.06 (0.94)
LNS 10.77 2.40 9.36 3.10 12.80 3.10 11.08 2.50 9.60 2.50 11.25 1.90 F1,79 = 0.04 (0.82) F2,79 = 2.00 (0.14)
Fluency −0.96 0.90 −2.04 0.65 −0.80 1.26 −0.71 1.00 −2.21 1.04 −0.12 0.72 F1,79 = 5.11 (0.02)* F2,79 = 3.36 (0.04)*
RWT_S-Words 12.13 3.80 8.64 2.70 12.90 4.20 13.47 4.30 9.42 4.50 17.10 3.90 F1,79 = 16.25 (0.00)** F2,79 = 2.54 (0.08)
RWT_Animals 21.13 4.50 16.73 2.90 22.10 6.70 21.40 4.60 14.50 4.70 22.80 4.70 F1,79 = 0.17 (0.67) F2,79 = 1.14 (0.33)
HRSchiz, High risk of schizophrenic psychosis; CONV, Converter; HRBip, high risk for bipolar disorder; TMT_A, Trail-Making Test, Version A; TMT_B, Trail-Making Test, Version
B; DSCT, Digit Symbol Coding Test; CPT, Continuous Performance Test (_RT, reaction time; _Omis, number of omissions); RAVLT, Rey Auditory Verbal Leaning Test (T1, trial 1;
ΣT1-5, sum of trials 1-5; recogn, recognition); DS, Digit Span; LNS, Letter-Number Sequencing; RWT, Verbal Fluency Test (Regensburger Wortflüssigkeits-Test); S.D., standard
deviation.





















converters to schizophrenia may show a diverging
course as members in the former group improved in
all cognitive domains except working memory while
performance by those in the latter group remained
stable. Second, the group of individuals who were
later identified as converters to schizophrenia was
already displaying a significantly lower level of gen-
eral performance at the baseline assessment compared
to the other two groups. Third, preliminarily, the
performance by HRBip individuals began at a higher
level than either HRSchiz or CONV participants, and
showed stable or improved performance from baseline
to follow-up. Across all groups, a reduction of positive
symptoms was strongly associated with improvements
in the fluency domain. In addition, it is important to
emphasize that methodological challenges, such as
the relatively short follow-up period or the small size
of HRBip group limit our interpretations.
In contrast with the assumption of a progressive
deteriorating path to psychosis, our sample of subjects
at risk for psychosis did not show a significant decline
in functioning but rather improvements that reached a
statistical threshold in the domains of speed, attention,
fluency, and learning/memory. Scores within the
working memory domain remained stable for all
three clinical groups. In subjects at risk for psychosis
who did not convert during the follow-up period,
improvements were observed over time in multiple
cognitive domains, specifically in processing speed,
verbal and visual learning, and memory. This has
also been reported previously (Keefe et al. 2006;
Becker et al. 2010; Barbato et al. 2013; Bora & Murray,
2013). One might explain these improvements as a
result of practice or placebo effects, such as increased
motivation or decreased anxiety, upon being exposed
to the same test a second time (Goldberg et al. 2010).
In the learning and memory domain persons from all
groups demonstrated improvements during the
follow-up assessment, although this change was not
statistically significant in the CONV group. Most likely
in this domain, a paradigm, as well as content-specific,
practice effect had occurred, i.e. familiarity with testing
instructions/demands or explicit learning of the same
words on a list. Likewise, an investigation by
Crespo-Facorro et al. (2009) found that healthy control
subjects had pronounced improvements in their Rey
Auditory Verbal Learning Test (Helmstaedter et al.
2001) and Visual Design and Learning Test (non-verbal
memory) (Spreen & Strauss, 1991) [effect sizes (ES) up
to 0.97] that contrasted with smaller improvements in
tests of attention (ES up to 0.2). In addition to such
practice effects, a reduction or stabilization in the
severity of symptoms at follow-up may substantially
contribute to cognitive improvements (Bora &
Murray, 2013). In our study, the observed association
between diminished positive symptoms and improve-
ment in fluency tasks across all groups may support
this proposition.
By contrast, CONV individuals did not show any
significant improvement in cognitive functioning
from baseline to follow-up but only consistencies in
performances over time. Similar findings have been
reported before (Keefe et al. 2006; Wood et al. 2007;
Bora & Murray, 2013). It is debatable to what extent
a practice effect can be abolished by an underlying pro-
gressive cognitive decline related to pathophysiologi-
cal changes. It is also conceivable that those in the
CONV group displayed the same level of performance
because they were immune to practice effects. The neu-
ronal systems relevant for practice and implicit learn-
ing may be specifically impaired in individuals
converting to psychosis. Besides, Bowie et al. (2012)
have noted that second-generation antipsychotic med-
ications in UHR individuals are associated with rela-
tively negative effects on cognition at follow-up
when compared with UHR subjects who are either
untreated or taking antidepressants. However, in our
study, the effects were still observable after carefully
controlling for neuroleptic medication.
Individuals classified as HRBip exhibited a higher
performance than the HRSchiz group. In line with
that, earlier studies found that premorbid deficits
seem to be absent, or even reversed, in bipolar dis-
order. This was shown in two longitudinal studies
where individuals with better cognitive functioning
in childhood or adolescence had an increased risk for
later bipolar disorder (Koenen et al. 2009; MacCabe
et al. 2010). However, the small size of the HRBip
group restricts the extent to which our finding can be
generalized. In addition, efforts to create diagnostic
tools for early detection of bipolar disorder have only
recently begun. This study applied recommended cut-
off scores in self-assessment instruments like HCL-32
as diagnostic criteria (Angst et al. 2005). A next essen-
tial step would be to critically verify the validity and
sensitivity of our approach and to compare it with
the meanwhile available scale for early recognition of
bipolar disorder (Correll et al. 2014).
Cognitive dysfunction has been regarded as a poss-
ible latent marker, or endophenotype, of genetic risk
for schizophrenia (e.g. Heinrichs & Zakzanis, 1998;
Cosway et al. 2000). According to the neuro-
developmental model, cognitive deficits are already
evident before the onset of psychosis. During baseline
testing, our sample group of ‘true’ at-risk individuals
with later conversion was exhibiting significantly
lower performances on the domains of processing
speed, fluency, learning/memory, and working mem-
ory, as well as a lower estimated pre-morbid IQ.
Thus, our results may confirm the assumption that
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neurocognitive deficits are present prior to the devel-
opment of psychosis (Cannon et al. 2006; Giuliano
et al. 2012; Fusar-Poli et al. 2012a; Müller et al. 2013;
Bora et al. 2014).
The findings regarding improvement in cognitive
function by individuals at risk of psychosis tend to
contradict the idea of a progressive decline in schizo-
phrenia. It is questionable whether there is a con-
tinuum that defines these reportedly smaller but
distinctly reduced performances by at-risk, but non-
converting individuals (Hambrecht et al. 2002; Brewer
et al. 2005; Keefe et al. 2006; Niendam et al. 2006;
Pukrop et al. 2006) and the intermediate deficits in
‘true’ positive individuals. The at-risk psychosis state
is characterized by a marked impairment in psycho-
social functioning (Velthorst et al. 2010), many
co-morbidities (Yung et al. 2008), and multiple mental
and functional deficits (Ruhrmann et al. 2010).
Furthermore, a meta-analysis has revealed a modest ef-
fect toward reduced transition risks in the most re-
cently published studies (Fusar-Poli et al. 2012b).
Accordingly, the transition rate apparently decreases
to 10–18% within 1 year (Yung & Nelson, 2013); our
results fell within this range. This means that, for a
substantial proportion of the subjects initially labelled
as at-risk, their conversion to psychosis may never
happen. Likewise, better performances by the at-risk
group than the converter group may hypothetically
be a result of a subset of ‘false positives’ within the
sample (Bora & Murray, 2013; Zipursky et al. 2013).
From a critical view, the cognitive deficits observed
in at-risk compared to healthy individuals at baseline
may reflect low psychosocial functioning in general
rather than a compelling degradation associated with
the path to manifestation of a disorder. It should be
noted that our study plan did not involve any thera-
peutic intervention. One part of the participants in
our study was treated by their resident psychiatrists
and psychologist in the sense of a treatment as usual.
Another part of the participants was not enrolled in
any therapeutic offers. For our study we documented
only the number and type of therapeutic contacts ant
the received medication. However, regardless of treat-
ment, non-converting subjects improved in positive
and negative symptomatology.
Above all, the declining transition rate in subjects at
risk for psychosis is a controversial issue, especially be-
cause a potential unnecessary diagnosis might give rise
to unintended consequences such as stigma and dis-
crimination (Yung et al. 2010). In particular, self-
labelling and perceived public stigma can be related
to heightened stress through stigma-associated cogni-
tions that delicately reduce the well-being of young
individuals diagnosed as at-risk (Rüsch et al. 2014).
Therefore, more research is urgently needed
concerning the possible side-effects of identifying a
person as being ‘at-risk of psychosis’ (Yung et al. 2012).
The results of this study should be considered in the
context of several limitations. The CONV and HRBip
groups were relatively small, therefore the statistical
power may be limited. The study project enabled
only a relatively short follow-up period and it cannot
be excluded, in fact, that a longer follow-up duration
would have provided on the one hand more transi-
tions, and on the other, evidence for a progressive cog-
nitive decline instead of stability in the converter
group. The duration of the follow-up would have
been needed to extend for several years to clarify if
the improvements represent a complete remission of
symptoms, how long the improvements will continue,
and to be sure that none of the individuals is falsely
diagnosed, which is quite challenging to realize.
Additionally, due to project-specific issues a follow-up
assessment of the healthy CG, which would have pro-
vided further insights, was not performed. Further,
there was a loss of 59% of individuals missing the
1-year follow-up assessment. A drop-out analysis
found no differences in demographic and clinical base-
line variables between subjects participating (nodrop)
and not participating (drop) at the follow-up assess-
ment. However, it cannot be excluded that with a
smaller drop-out rate the study’s results would be
modified. However, our study benefited from the rela-
tively large group of HRSchiz subjects in a longitudinal
design, and the fact that we could control for con-
founding variables.
In summary, the at-risk psychosis sample comprised
a heterogeneous group of individuals who performed
at a lower level on neurocognitive tests when com-
pared with healthy individuals. The neurocognitive
performance in HRSchiz and HRBip improved over
the duration of the follow-up period, and remained
stable in the CONV group. Generally, in the help-
seeking individuals, a substantial degree of recovery
and spontaneous remission of psychopathological
symptoms was observed over the duration of the
study. Further studies with longer follow-up periods
are needed to clarify the continuing course of their
psycho-social functioning and neurocognitive perform-
ance. Moreover, further research is needed to verify
and advance the approaches to create diagnostic
tools for early detection of bipolar disorder.
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